Artificial and bioartificial liver support

Seminars in Liver Disease

Volumn 28, Issue 2, 2008, Pages 210-217

  McKenzie, Travis J ^a   Lillegard, Joseph B ^a   Nyberg, Scott L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute liver failure; Artificial liver; Bioartificial liver; Liver support device

Indexed keywords

ALBUMIN DIALYSIS; ARTIFICIAL LIVER; BIOARTIFICIAL LIVER; DONOR; HUMAN; LIVER FAILURE; LIVER FUNCTION; LIVER SUPPORT; LIVER TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EXTRACORPOREAL CIRCULATION; HEPATOCYTES; HUMANS; LIVER FAILURE, ACUTE; LIVER, ARTIFICIAL; MEMBRANES, ARTIFICIAL; PLASMAPHERESIS; RENAL DIALYSIS;

EID: 43049099022     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1073120     Document Type: Review

References (50)

1. Khashab M, Tector AJ, Kwo PY. Epidemiology of acute liver failure. Curr Gastroenterol Rep 2007;9:66-73
2. Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954
3. Farges O, Kalil AN, Samuel D, et al. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients. Transplantation 1995;59:1124-1133
4. Sorrentino F. Prime ricerche per la realizzatione di un fegato artificiale. Chir Patol Sper 1956;4:1401
5. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin bound toxins. Artif Organs 1993;17:809-813
6. Stange J, Mitzner S, Risler T, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23:319-330
7. Steiner C, Sen S, Stange J, Williams R, Jalan R. Binding of bilirubin and bromosulphthalein to albumin: implications for understanding the pathophysiology of liver failure and its management. Liver Transpl 2004;10:1531-1538
8. Awad SS, Swaniker F, Magee J, Punch J, Bartlett RH. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001;130:354-362
9. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004;10:1099-1106
10. Novelli G, Rossi M, Pugliese F, et al. Molecular adsorbents recirculating system treatment in acute-on-chronic hepatitis patients on the transplant waiting list improves model for end-stage liver disease scores. Transplant Proc 2007;39:1864-1867
11. Falkenhagen D, Strobl W, Vogt G, et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 1999;23:81-86
12. Santoro A, Faenza S, Mancini E, et al. Prometheus system: a technological support in liver failure. Transplant Proc 2006;38:1078-1082
13. Rifai K, Ernst T, Kretschmer U, et al. Prometheus: a new extracorporeal system for the treatment of liver failure. J Hepatol 2003;39:984-990
14. Herget-Rosenthal S. Citrate anticoagulated modified fractionated plasma separation and adsorption: first clinical efficacy and safety data in liver failure. J Am Soc Nephrol 2003;14:729A
15. Kramer L. Clinical experience with artifical liver support in chronic liver failure with encephalopathy [abstract]. ASAIO J 2000:a211
16. Evenepoel P, Laleman W, Wilmer A, et al. Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Artif Organs 2006;30:276-284
17. Sussman NL, Kelly JH. Extracorporeal liver support: cell-based therapy for the failing liver. Am J Kidney Dis 1997;30(suppl 4):S66-S71
18. Allen JW, Hassanein T, Bhatia SN. Advances in bioartificial liver devices. Hepatology 2001;34:447-455
19. Spray DC, Fujita M, Saez JC, et al. Proteoglycans and glycosaminoglycans induce gap junction synthesis and function in primary liver cultures. J Cell Biol 1987;105:541-551
20. Yarmush ML, Dunn JC, Tompkins RG. Assessment of artificial liver support technology. Cell Transplant 1992;1:323-341
21. Ellis AJ, Hughes RD, Nicholl D, et al. Temporary extracorporeal liver support for severe acute alcoholic hepatitis using BioLogic-DT. Int J Artif Organs 1999;22:27-34
22. Nyberg SL, Remmel RP, Mann HJ, et al. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg 1994;220:59-67
23. Ellis AJ, Sussman NL, Kelly JH, Williams R. Clinical experience with an extracorporeal liver assist device. In: Lee W, Williams R, eds. Acute Liver Failure. Cambridge: Cambridge University Press; 1997:255-265
24. Mavri-Damelin D, Damelin LH, Eaton S, et al. Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng 2008;99:644-651
25. Ellis AJ, Hughes RD, Wendon J, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446-1451
26. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997;3:282-286
27. Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs 1994;18:390-396
28. Patience C, Patton GS, Takeuchi Y, et al. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet 1998;352:699-701
29. Paradis K, Langford G, Long Z, et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science 1999;285:1236-1241
30. Pitkin Z, Switzer W, Chapman L. An interim analysis of PERV infectivity in 74 patients treated with a bioartificial liver in a prospective, randomized, multicenter controlled trial. Hepatology 2001;34:249A
31. Watanabe FD, Mullon CJ, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure: a phase I clinical trial. Ann Surg 1997;225:484-491
32. Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660-667
33. Sauer IM, Kardassis D, Zeillinger K, et al. Clinical extracorporeal hybrid liver support: phase I study with primary porcine liver cells. Xenotransplantation 2003;10:460-469
34. Mazariegos GV, Kramer DJ, Lopez RC, et al. Safety observations in phase I clinical evaluation of the Excorp Medical bioartificial liver support system after the first four patients. ASAIO J 2001;47:471-475
35. Van De Kerkhove MP, Di Florio E, Scuderi V, et al. Phase I clinical trial with the AMC-bioartificial liver. Int J Artif Organs 2002;25:950-959
36. Uchino J, Tsuburaya T, Kumagai F, et al. A hybrid bioartificial liver composed of multiplated hepatocyte monolayers. ASAIO Trans 1988;34:972-977
37. Margulis MS, Erukhimov EA, Andreiman LA, Viksna LM. Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency. Resuscitation 1989;18:85-94
38. Matsumura KN, Guevara GR, Huston H, et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 1987;101:99-103
39. Matsushita T, Amiot B, Hardin J, Piatt JL, Nyberg SL. Membrane pore size impacts performance of a xenogeneic bioartificial liver. Transplantation 2003;76:1299-1305
40. Nyberg SL, Hardin J, Amiot B, et al. Rapid, large-scale formation of porcine hepatocyte spheroids in a novel spheroid reservoir bioartificial liver. Liver Transpl 2005;11:901-910
41. Cascio SM. Novel strategies for immortalization of human hepatocytes. Artif Organs 2001;25:529-538
42. Kulig KM, Vacanti JP. Hepatic tissue engineering. Transpl Immunol 2004;12(3-4):303-310
43. Okamura K, Asahina K, Fujimori H, et al. Generation of hybrid hepatocytes by cell fusion from monkey embryoid body cells in the injured mouse liver. Histochem Cell Biol 2006;125:247-257
44. Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165:901-912
45. Sandgren EP, Palmiter RD, Heckel JL, et al. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 1991;66:245-256
46. Sandgren EP, Merlino G. Hepatocarcinogenesis in transgenic mice. Prog Clin Biol Res 1995;391:213-222
47. Rhim JA, Sandgren EP, Palmiter RD, Brinster RL. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc Natl Acad Sci U S A 1995;92:4942-4946
48. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007;25:903-910
49. Grompe M, Lindstedt S, Al-Dhalimy M, et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 1995;10:453-460
50. Overturf K, Al-Dhalimy M, Manning K, Ou CN, Finegold M, Grompe M. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I. Hum Gene Ther 1998;9:295-304